R&D Pipeline

New Medicines for UnderservedGut-Brain Axis Disorders

Bioactive, human-equivalent oligosaccharides with the potential to be transformative new medicines by modulating the gut microbiome and immune system.

Our Focus

Company Overview

Our Investors


By developing new drugs from some of the safest bioactive compounds on the planet.


Standard of care in diseases where current treatments have significant limitations.


What a truly safe, effective, and financially accessible drug means to the healthcare system.


Human Milk Oligosaccharides as Medicine

R & D Pipeline

OM002 (2’FL)
Irritable Bowel Syndrome - Constipation
Irritable Bowel Syndrome - Diarrhea
OM001 (3’SL)
Rheumatoid & Juvenile Idiopathic Arthritis
Atopic Dermatitis
Autism Spectrum Disorder
OM003 (6’SL)
Autism Spectrum Disorder

Our Team

Scientific Advisory Board

To support the research, preclinical and clinical development of our OM candidates, we have assembled an SAB with extensive expertise in the biology of HMOs, understanding of inflammatory conditions and the scaled synthetic-biology manufacturing of HMOs.

Angela Christiano, PhD

John McCoy, PhD

David Newburg, PhD

Ardythe Morrow, PhD

Medical Advisory Board

OM002 Irritable Bowel Syndrome Medical Advisory Board

Brian Lacy, MD, PhD

Nicholas Talley, MD, PhD

Anthony Lembo, MD

Purna Kashyap, MB BS, PhD

Medical Advisory Board

OM001 Medical Advisory Board

Daniel Lovell, M.D.

Steve Hughes, M.D.


Glycosyn is a pioneer in the synthetic biology that has enabled the commercial-scale production of HMOs to supply the infant formula market, enabling clinical supply of OM002, OM001 and OM003.  In addition, the scientific founders of Glycosyn are world experts in human milk oligosaccharides who invented the key intellectual property covering OM002 (2’FL) for the treatment of Irritable Bowel Syndrome and Inflammatory Bowel Disease to which we have an exclusive therapeutic license through this collaboration.

Arpeggio is a machine learning transcriptomics company focused on understanding biology differently through measuring active transcription of RNA.  Our collaboration was formed in 2020 and we have exclusive rights to their platform for the characterization of HMOs to elucidate potential therapeutic mechanism in context of disease states.  Through this collaboration we have already uncovered biology at the transcription level not yet observed with HMOs in the context of disease models.

News & Press Releases

Consequatur Sint Quia Qui

Sequi eos quisquam repudiandae iusto quia commodi illum quia itaque. Omnis praesentium quaerat. Non repellendus laborum est. Quae doloremque aspernatur culpa rerum. Vero et consequat

Quo Omnis Reiciendis

Animi molestiae consectetur iure esse facere est in ipsa. Iste in a. Repellendus laborum odio ea. Laboriosam numquam quasi voluptas quisquam molestiae doloremque placeat voluptate. Voluptate pariatur optio ipsam. Neque necessitat


Dolor beatae est iste molestiae soluta vel aspernatur. Officia molestiae excepturi voluptas aut voluptas. Cumque quis quis accusantium. Facere voluptatem repellendus aperiam molestiae aspernatur vel eos. Autem est iste distinctio in. Et ut vel aut quia. Quia omnis ipsam. Architecto accus

Contact Us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.